secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELI LILLY & Co (LLY)
CIK:        0000059478
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0000059478-21-000168
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lilly Q2 revenue $6.74B (+23% YoY); non-GAAP EPS $1.87 (+29%); updates 2021 guidance
--------------------------------------------------------------------------------

- Revenue $6.74B (+23% YoY); volume growth 22%; non-GAAP EPS $1.87 (+29% YoY).
- Reported EPS $1.53 (-1% YoY) due to $423M COVID antibody inventory charge.
- 2021 GAAP EPS guidance updated to $6.73-$6.93; non-GAAP unchanged at $7.80-$8.00.
- Key products: Trulicity +25%, Taltz +44%, Verzenio +64%; pipeline milestones for tirzepatide, Jardiance, donanemab.
- Board authorizes $5B share repurchase; acquires Protomer; global collaboration with MiNA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000168/0000059478-21-000168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/59478/000005947821000168/lly-20210803.htm
  HTML page:      https://secwatch.observer/filing/0000059478-21-000168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer